Bulletin of Experimental Biology and Medicine

, Volume 117, Issue 3, pp 249–252 | Cite as

Peculiarities of changes in the rate of cholesterol synthesis in lymphocytes and lipid and lipoprotein peripheral blood levels in patients with ischemic heart disease and hypercholesterolemia in the course of combined treatment with lovastatin and obsidan

  • E. D. Polyakova
  • T. N. Ivanova
  • S. E. Nikulina
  • V. A. Metel'skaya
  • A. M. Olfer'ev
  • I. A. Shcherbakova
  • N. M. Akhmedzhanov
  • N. V. Perova
Biophysics and Biochemistry

Abstract

It is shown that the level of total serum cholesterol dropped and the rate of cholesterol synthesis in lymphocytes remained unchanged after 12 months of lovastatin treatment (20 mg/day) in patients with coronary heart disease. The administration of lovastatin abolished the deleterious effect of obsidan on the blood lipid spectrum.

Key Words

lymphocytes cholesterol synthesis lovastatin hypercholesterolemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    R. G. Oganov, I. I. Mustafaev, N. V. Perova, et al.,Kardiologiya,25, 44 (1985).PubMedGoogle Scholar
  2. 2.
    A. Boyum,Scand. J. Clin. Lab. Invest.,21, 77 (1968).Google Scholar
  3. 3.
    M. Burnstein, H. R. Scholnick, and R. Morfin,J. Lipid Res.,11, 583 (1979).Google Scholar
  4. 4.
    M. D. Curry, A. Gustafson, P. Alaupovic and W. J. McConathy,Clin. Chem. 24, 280 (1978).PubMedGoogle Scholar
  5. 5.
    J. A. Cuthbert and P. E. Lipsky,J. Biol. Chem.,262, 7808 (1987).PubMedGoogle Scholar
  6. 6.
    S. M. Grundy and G. L. Vega,J. Lipid Res.,26, 1454, (1985).Google Scholar
  7. 7.
    F. C. Hagemenas and D. R. Illingworth,Arteriosclerosis,9, 355 (1989).PubMedGoogle Scholar
  8. 8.
    F. C. Hagemenas, A. S. Pappu, and D. R. Illingworth,Europ. J. Clin. Invest.,20, 150 (1990).PubMedGoogle Scholar
  9. 9.
    H. J. Harwood, D. M. Bridge, and P. W. Stacpoole,J. Clin. Invest.,79, 1125 (1987).PubMedCrossRefGoogle Scholar
  10. 10.
    J. M. Hoeg and H. B. Brewer,JAMA,258, 3532 (1987).PubMedCrossRefGoogle Scholar
  11. 11.
    D. R. Illingworth, S. R. Bacon, and K. K. Larsen,Atheroscl. Rev.,18, 161 (1988).Google Scholar
  12. 12.
    P. Roeschlau, E. Bernt, and W. Gruber,Klin. Chem. Klin. Biochem.,12, 226 (1974).Google Scholar
  13. 13.
    B. G. Stone, C. D. Evans, W. F. Prigge, et al.,J. Lipid Res.,32, 71 (1991).PubMedGoogle Scholar
  14. 14.
    E. E. Sundberg and D. R. Illingworth,Proc. Nat. Acad. Sci. USA,80, 7631 (1983).PubMedCrossRefGoogle Scholar
  15. 15.
    V. V. Tertov, E. I. Chazov, A. N. Orekhov, et al.,Lancet,2, 595 (1986).PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • E. D. Polyakova
    • 1
  • T. N. Ivanova
    • 1
  • S. E. Nikulina
    • 1
  • V. A. Metel'skaya
    • 1
  • A. M. Olfer'ev
    • 1
  • I. A. Shcherbakova
    • 1
  • N. M. Akhmedzhanov
    • 1
  • N. V. Perova
    • 1
  1. 1.Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, National Research Center of Preventive MedicineMinistry of Health of the Russian FederationMoscow

Personalised recommendations